Key result
Atorvastatin plus vitamins C and E fails to significantly reduce composite ASCVD events vs placebo.
Why the study?
Does treatment with atorvastatin, vitamin C, and vitamin E reduce ASCVD events and progression of coronary calcification in asymptomatic adults with elevated coronary calcium scores?
RCT (n=1,005)
Double-blind
randomized
Does treatment with atorvastatin, vitamin C, and vitamin E reduce ASCVD events and progression of coronary calcification in asymptomatic adults with elevated coronary calcium scores?
Absolute Event Rate: 6.9% vs 9.9%
p-value: p=0.08
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Increasing the accuracy of risk stratification through the use of fast CT scanning provides a very direct benefit to patients. Many patients classified at intermediate risk with clear signs of underlying disease can get potentially life-saving treatment, while others with no signs of disease can be spared an unnecessary and expensive regimen of medications.”
In asymptomatic adults with elevated coronary calcium scores, treatment with atorvastatin, vitamin C, and vitamin E did not significantly reduce ASCVD events or slow the progression of coronary calcification.
Arad et al. (2005) conducted an RCT in Elevated coronary calcium scores (n=1,005). Atorvastatin, vitamin C, and vitamin E vs. matching placebos was evaluated on composite of all ASCVD events (p=0.08). Treatment with atorvastatin, vitamin C, and vitamin E did not significantly reduce the primary composite of all ASCVD events compared to placebo (6.9% vs. 9.9%, p=0.08).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: